دورية أكاديمية
Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma.
| العنوان: | Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. |
|---|---|
| المؤلفون: | Bendandi M; Laboratory of Immunotherapy, Oncology Division, Center for Applied Medical Research, University of Navarra, Pamplona, Spain., Marillonnet S; Icon Genetics GmbH, Halle, Germany., Kandzia R; Icon Genetics GmbH, Halle, Germany., Thieme F; Icon Genetics GmbH, Halle, Germany., Nickstadt A; Icon Genetics GmbH, Halle, Germany., Herz S; Icon Genetics GmbH, Halle, Germany., Fröde R; Icon Genetics GmbH, Halle, Germany., Inogés S; Laboratory of Immunotherapy, Oncology Division, Center for Applied Medical Research, University of Navarra, Pamplona, Spain., Lòpez-Dìaz de Cerio A; Laboratory of Immunotherapy, Oncology Division, Center for Applied Medical Research, University of Navarra, Pamplona, Spain., Soria E; Laboratory of Immunotherapy, Oncology Division, Center for Applied Medical Research, University of Navarra, Pamplona, Spain., Villanueva H; Laboratory of Immunotherapy, Oncology Division, Center for Applied Medical Research, University of Navarra, Pamplona, Spain., Vancanneyt G; Bayer BioScience, Gent, Belgium., McCormick A; Matrix Bioresearch, Vacaville, CA, USA., Tusé D; DT/Consulting Group., Lenz J; Bayer Schering Pharma, Wuppertal, Germany., Butler-Ransohoff JE; Bayer Innovation GmbH, Duesseldorf, Germany., Klimyuk V; Icon Genetics GmbH, Halle, Germany., Gleba Y; Icon Genetics GmbH, Halle, Germany. Electronic address: gleba@icongenetics.de. |
| المصدر: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2010 Dec; Vol. 21 (12), pp. 2420-2427. Date of Electronic Publication: 2010 May 21. |
| نوع المنشور: | Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2020- : London : Elsevier Original Publication: Dordrecht ; Boston : Kluwer Academic Publishers, c1990- |
| مواضيع طبية MeSH: | Cancer Vaccines/*biosynthesis , Immunoglobulin Idiotypes/*metabolism , Lymphoma, Non-Hodgkin/*immunology , Lymphoma, Non-Hodgkin/*therapy , Plantibodies/*metabolism, Agrobacterium tumefaciens/genetics ; Agrobacterium tumefaciens/immunology ; Agrobacterium tumefaciens/metabolism ; Animals ; Cancer Vaccines/genetics ; Cancer Vaccines/immunology ; Cancer Vaccines/isolation & purification ; Cloning, Molecular ; Efficiency ; Gene Expression Regulation, Plant ; Humans ; Immunoglobulin Idiotypes/genetics ; Immunoglobulin Idiotypes/immunology ; Individuality ; Mice ; Mice, Inbred C3H ; Plantibodies/genetics ; Plantibodies/isolation & purification ; Plants, Genetically Modified/genetics ; Plants, Genetically Modified/immunology ; Plants, Genetically Modified/metabolism ; Time Factors ; Vaccines, Synthetic/biosynthesis ; Vaccines, Synthetic/genetics ; Vaccines, Synthetic/immunology ; Vaccines, Synthetic/isolation & purification |
| مستخلص: | Background: Animal and clinical studies with plant-produced single-chain variable fragment lymphoma vaccines have demonstrated specific immunogenicity and safety. However, the expression levels of such fragments were highly variable and required complex engineering of the linkers. Moreover, the downstream processing could not be built around standard methods like protein A affinity capture. Design: We report a novel vaccine manufacturing process, magnifection, devoid of the above-mentioned shortcomings and allowing consistent and efficient expression in plants of whole immunoglobulins (Igs). Results: Full idiotype (Id)-containing IgG molecules of 20 lymphoma patients and 2 mouse lymphoma models were expressed at levels between 0.5 and 4.8 g/kg of leaf biomass. Protein A affinity capture purification yielded antigens of pharmaceutical purity. Several patient Igs produced in plants showed specific cross-reactivity with sera derived from the same patients immunized with hybridoma-produced Id vaccine. Mice vaccinated with plant- or hybridoma-produced Igs showed comparable protection levels in tumor challenge studies. Conclusions: This manufacturing process is reliable and robust, the manufacturing time from biopsy to vaccine is <12 weeks and the expression and purification of antigens require only 2 weeks. The process is also broadly applicable for manufacturing monoclonal antibodies in plants, providing 50- to 1000-fold higher yields than alternative plant expression methods. |
| المشرفين على المادة: | 0 (Cancer Vaccines) 0 (Immunoglobulin Idiotypes) 0 (Plantibodies) 0 (Vaccines, Synthetic) |
| تواريخ الأحداث: | Date Created: 20100525 Date Completed: 20110314 Latest Revision: 20200626 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1093/annonc/mdq256 |
| PMID: | 20494963 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1569-8041 |
|---|---|
| DOI: | 10.1093/annonc/mdq256 |